Payment overview · 2025
General Payments
$533.64
26 reported records · 14 companies
Healthcare provider profile · identity verified
Nipun Patel, M.D.
Allopathic & Osteopathic Physicians|Internal Medicine · CHAMBLEE, GA · NPI 1417990987
Verified facts
What the public records show
CMS Open Payments records show Nipun Patel, M.D. received $533.64 in general payments during 2025 across 26 reported records.
Bayer Healthcare Pharmaceuticals Inc. accounted for 16.7% of that reported general-payment amount.
The Open Payments records used for this analysis explicitly named 19 associated products.
A separate comparison found the same explicitly named product in public Medicare Part D data: Ozempic, Rybelsus.
ABBVIE INC. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported LINZESS as an associated drug or biological on 87954 records involving 21815 distinct recipient NPIs. Public Medicare Part D data also shows 26 claims for Linzess by this doctor in 2024.
Amgen Inc. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported PROLIA as an associated drug or biological on 20867 records involving 11744 distinct recipient NPIs. Public Medicare Part D data also shows 57 claims for Prolia by this doctor in 2024.
AstraZeneca Pharmaceuticals LP reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported FARXIGA as an associated drug or biological on 106133 records involving 42906 distinct recipient NPIs. Public Medicare Part D data also shows 18 claims for Farxiga by this doctor in 2024.
Lilly USA, LLC reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported JARDIANCE as an associated drug or biological on 47708 records involving 23833 distinct recipient NPIs. Public Medicare Part D data also shows 95 claims for Jardiance by this doctor in 2024.
Novo Nordisk Inc reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported Ozempic as an associated drug or biological on 261625 records involving 77793 distinct recipient NPIs. Public Medicare Part D data also shows 77 claims for Ozempic by this doctor in 2024.
Novo Nordisk Inc reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported Rybelsus as an associated drug or biological on 161257 records involving 55409 distinct recipient NPIs. Public Medicare Part D data also shows 18 claims for Rybelsus by this doctor in 2024.
PFIZER INC. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported ELIQUIS as an associated drug or biological on 87112 records involving 36032 distinct recipient NPIs. Public Medicare Part D data also shows 61 claims for Eliquis by this doctor in 2024.
PFIZER INC. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported PAXLOVID as an associated drug or biological on 24465 records involving 15715 distinct recipient NPIs. Public Medicare Part D data also shows 12 claims for Paxlovid by this doctor in 2024.
These records do not establish that a payment influenced prescribing or medical care.
Separate record types
Research & Ownership
Research Payments (direct recipient): not present in the loaded data
Associated Research Funding (for example, named PI): not present in the loaded data
Ownership / Investment: not present in the loaded data
These categories are never added into the General Payments headline. Associated research funding must not be described as money the doctor personally received unless the source record supports that conclusion.
Who paid this doctor?
Companies in 2025 General Payments
| Reported company | Canonical company | Amount | Share | Records | Year |
|---|---|---|---|---|---|
| Bayer Healthcare Pharmaceuticals Inc. | Unresolved — no canonical attribution shown | $89.29 | 16.7% | 4 | 2025 |
| ITI, Inc. (d/b/a Intra-Cellular Therapies, Inc.) | Unresolved — no canonical attribution shown | $79.34 | 14.9% | 3 | 2025 |
| SHIELD THERAPEUTICS INC | Unresolved — no canonical attribution shown | $72.77 | 13.6% | 3 | 2025 |
| ABBVIE INC. | Unresolved — no canonical attribution shown | $51.49 | 9.7% | 3 | 2025 |
| Novo Nordisk Inc | Unresolved — no canonical attribution shown | $41.42 | 7.8% | 2 | 2025 |
| PFIZER INC. | Unresolved — no canonical attribution shown | $40.44 | 7.6% | 2 | 2025 |
| Paratek Pharmaceuticals, Inc. | Unresolved — no canonical attribution shown | $31.98 | 6.0% | 2 | 2025 |
| Xeris Pharmaceuticals, Inc. | Unresolved — no canonical attribution shown | $24.40 | 4.6% | 1 | 2025 |
| AstraZeneca Pharmaceuticals LP | Unresolved — no canonical attribution shown | $20.41 | 3.8% | 1 | 2025 |
| Sumitomo Pharma America, Inc. | Unresolved — no canonical attribution shown | $19.45 | 3.6% | 1 | 2025 |
| Lilly USA, LLC | Unresolved — no canonical attribution shown | $18.83 | 3.5% | 1 | 2025 |
| Seqirus USA Inc | Unresolved — no canonical attribution shown | $16.10 | 3.0% | 1 | 2025 |
| Amgen Inc. | Unresolved — no canonical attribution shown | $13.89 | 2.6% | 1 | 2025 |
| Exact Sciences Corporation | Unresolved — no canonical attribution shown | $13.83 | 2.6% | 1 | 2025 |
What were the payments for?
Payment categories
| Category | Amount | Records |
|---|---|---|
| Food and Beverage | $533.64 | 26 |
A meal, consulting fee, royalty, and travel payment describe different kinds of reported relationships and should not be interpreted as equivalent.
Analysis 1 · Payment-linked products
Products named in Open Payments records
| Reported product | Type | Reported company | Related amount* | Records | Year |
|---|---|---|---|---|---|
| Kerendia Normalized: kerendia |
Drug | Bayer Healthcare Pharmaceuticals Inc. | $89.29 | 4 | 2025 |
Source payment records
|
|||||
| CAPLYTA Normalized: caplyta |
Drug | ITI, Inc. (d/b/a Intra-Cellular Therapies, Inc.) | $79.34 | 3 | 2025 |
Source payment records
|
|||||
| ACCRUFER Normalized: accrufer |
Drug | SHIELD THERAPEUTICS INC | $72.77 | 3 | 2025 |
Source payment records
|
|||||
| VRAYLAR Normalized: vraylar |
Drug | ABBVIE INC. | $51.49 | 3 | 2025 |
Source payment records
|
|||||
| Ozempic Normalized: ozempic |
Drug | Novo Nordisk Inc | $41.42 | 2 | 2025 |
Source payment records
|
|||||
| Rybelsus Normalized: rybelsus |
Drug | Novo Nordisk Inc | $41.42 | 2 | 2025 |
Source payment records
|
|||||
| PREVNAR 20 Normalized: prevnar 20 |
Biological | PFIZER INC. | $40.44 | 2 | 2025 |
Source payment records
|
|||||
| NUZYRA Normalized: nuzyra |
Drug | Paratek Pharmaceuticals, Inc. | $31.98 | 2 | 2025 |
Source payment records
|
|||||
| GVOKE HYPOPEN Normalized: gvoke hypopen |
Drug | Xeris Pharmaceuticals, Inc. | $24.40 | 1 | 2025 |
Source payment records
|
|||||
| AIRSUPRA Normalized: airsupra |
Drug | AstraZeneca Pharmaceuticals LP | $20.41 | 1 | 2025 |
Source payment records
|
|||||
| GEMTESA Normalized: gemtesa |
Drug | Sumitomo Pharma America, Inc. | $19.45 | 1 | 2025 |
Source payment records
|
|||||
| MOUNJARO Normalized: mounjaro |
Drug | Lilly USA, LLC | $18.83 | 1 | 2025 |
Source payment records
|
|||||
| ABRYSVO Normalized: abrysvo |
Biological | PFIZER INC. | $17.43 | 1 | 2025 |
Source payment records
|
|||||
| COMIRNATY Normalized: comirnaty |
Biological | PFIZER INC. | $17.43 | 1 | 2025 |
Source payment records
|
|||||
| Fluad Normalized: fluad |
Biological | Seqirus USA Inc | $16.10 | 1 | 2025 |
Source payment records
|
|||||
| Flucelvax Normalized: flucelvax |
Biological | Seqirus USA Inc | $16.10 | 1 | 2025 |
Source payment records
|
|||||
| OTEZLA Normalized: otezla |
Drug | Amgen Inc. | $13.89 | 1 | 2025 |
Source payment records
|
|||||
| REPATHA Normalized: repatha |
Biological | Amgen Inc. | $13.89 | 1 | 2025 |
Source payment records
|
|||||
| Cologuard Collection Kit Normalized: cologuard collection kit |
Device | Exact Sciences Corporation | $13.83 | 1 | 2025 |
Source payment records
|
|||||
* Product-associated amounts are non-additive because one payment record may name more than one product.
These products were named on specific Open Payments records. A named product does not show that the payment influenced treatment or prescribing.
Public prescribing for products named in payments
| Open Payments product | Payment year | Part D brand | Part D year | Claims | Match method | Source |
|---|---|---|---|---|---|---|
| Ozempic ozempic |
2025 | Ozempic | 2024 | 77 | exact normalized | Medicare Part D |
| Rybelsus rybelsus |
2025 | Rybelsus | 2024 | 18 Beneficiary count suppressed |
exact normalized | Medicare Part D |
The presence of the same drug in both datasets does not show that a payment caused or influenced a prescription.
Analysis 2 · Same-company prescribing overlap
Drugs reported in other payments from the same company that also appear in Medicare Part D
This analysis is independent from products named on this doctor’s individual payment records. A row appears only when the exact Open Payments reporting entity paid this doctor, that same reporting entity reported the drug or biological on at least 10 loaded General Payment records involving at least 2 distinct recipient NPIs, and this doctor has the same non-generic brand in public Part D data. This does not mean the company owns or manufactures the drug.
| Paying company | Payment year | Drug reported by same entity | Open Payments evidence | Part D | Claims | Beneficiaries |
|---|---|---|---|---|---|---|
| ABBVIE INC. Exact reporting entity; no affiliate inference |
2025 | LINZESS open payments reported associated product |
CMS Open Payments — General Payments 87954 supporting records · 21815 recipient NPIs · example record 1201352608 |
Linzess · 2024 Exact normalized brand match · 1 Part D row |
26 | suppressed by CMS |
| Amgen Inc. Exact reporting entity; no affiliate inference |
2025 | PROLIA open payments reported associated product |
CMS Open Payments — General Payments 20867 supporting records · 11744 recipient NPIs · example record 1226874448 |
Prolia · 2024 Exact normalized brand match · 1 Part D row |
57 | 38 |
| AstraZeneca Pharmaceuticals LP Exact reporting entity; no affiliate inference |
2025 | FARXIGA open payments reported associated product |
CMS Open Payments — General Payments 106133 supporting records · 42906 recipient NPIs · example record 1206131362 |
Farxiga · 2024 Exact normalized brand match · 1 Part D row |
18 | suppressed by CMS |
| Lilly USA, LLC Exact reporting entity; no affiliate inference |
2025 | JARDIANCE open payments reported associated product |
CMS Open Payments — General Payments 47708 supporting records · 23833 recipient NPIs · example record 1186464557 |
Jardiance · 2024 Exact normalized brand match · 1 Part D row |
95 | 37 |
| Novo Nordisk Inc Exact reporting entity; no affiliate inference |
2025 | Ozempic open payments reported associated product |
CMS Open Payments — General Payments 261625 supporting records · 77793 recipient NPIs · example record 1188130076 |
Ozempic · 2024 Exact normalized brand match · 1 Part D row |
77 | 18 |
| Novo Nordisk Inc Exact reporting entity; no affiliate inference |
2025 | Rybelsus open payments reported associated product |
CMS Open Payments — General Payments 161257 supporting records · 55409 recipient NPIs · example record 1188130076 |
Rybelsus · 2024 Exact normalized brand match · 1 Part D row |
18 | suppressed by CMS |
| PFIZER INC. Exact reporting entity; no affiliate inference |
2025 | ELIQUIS open payments reported associated product |
CMS Open Payments — General Payments 87112 supporting records · 36032 recipient NPIs · example record 1228794063 |
Eliquis · 2024 Exact normalized brand match · 1 Part D row |
61 | 18 |
| PFIZER INC. Exact reporting entity; no affiliate inference |
2025 | PAXLOVID open payments reported associated product |
CMS Open Payments — General Payments 24465 supporting records · 15715 recipient NPIs · example record 1228794432 |
Paxlovid · 2024 Exact normalized brand match · 1 Part D row |
12 | suppressed by CMS |
These facts do not show that a payment was for the drug, that the company owns or manufactures the drug, or that a payment caused or influenced prescribing.
Public Medicare Part D data
Provider-and-drug rows loaded for 2024
| Brand | Generic | Claims | Beneficiaries |
|---|---|---|---|
| Rosuvastatin Calcium | Rosuvastatin Calcium | 630 | 194 |
| Atorvastatin Calcium | Atorvastatin Calcium | 597 | 187 |
| Amlodipine Besylate | Amlodipine Besylate | 560 | 189 |
| Metformin Hcl | Metformin Hcl | 370 | 125 |
| Lisinopril | Lisinopril | 325 | 104 |
| Losartan Potassium | Losartan Potassium | 300 | 86 |
| Levothyroxine Sodium | Levothyroxine Sodium | 266 | 82 |
| Omeprazole | Omeprazole | 256 | 99 |
| Pantoprazole Sodium | Pantoprazole Sodium | 177 | 71 |
| Gabapentin | Gabapentin | 172 | 62 |
| Metoprolol Succinate | Metoprolol Succinate | 166 | 50 |
| Metformin Hcl Er | Metformin Hcl | 159 | 52 |
| Zolpidem Tartrate | Zolpidem Tartrate | 145 | 25 |
| Alprazolam | Alprazolam | 144 | 27 |
| Trazodone Hcl | Trazodone Hcl | 138 | 50 |
| Tamsulosin Hcl | Tamsulosin Hcl | 130 | 48 |
| Carvedilol | Carvedilol | 129 | 40 |
| Glimepiride | Glimepiride | 113 | 29 |
| Fluticasone Propionate | Fluticasone Propionate | 105 | 57 |
| Jardiance | Empagliflozin | 95 | 37 |
| Januvia | Sitagliptin Phosphate | 92 | 27 |
| Diclofenac Sodium | Diclofenac Sodium | 91 | 33 |
| Albuterol Sulfate Hfa | Albuterol Sulfate | 89 | 36 |
| Lisinopril-Hydrochlorothiazide | Lisinopril/Hydrochlorothiazide | 86 | 22 |
| Alendronate Sodium | Alendronate Sodium | 81 | 28 |
| Ozempic | Semaglutide | 77 | 18 |
| Losartan-Hydrochlorothiazide | Losartan/Hydrochlorothiazide | 75 | 28 |
| Cyclobenzaprine Hcl | Cyclobenzaprine Hcl | 72 | 35 |
| Hydrochlorothiazide | Hydrochlorothiazide | 71 | 28 |
| Tramadol Hcl | Tramadol Hcl | 70 | 27 |
| Azithromycin | Azithromycin | 69 | 60 |
| Pioglitazone Hcl | Pioglitazone Hcl | 69 | 24 |
| Simvastatin | Simvastatin | 69 | 22 |
| Metoprolol Tartrate | Metoprolol Tartrate | 68 | 21 |
| Furosemide | Furosemide | 67 | 23 |
| Glipizide | Glipizide | 67 | 23 |
| Atenolol | Atenolol | 65 | 20 |
| Famotidine | Famotidine | 65 | 31 |
| Allopurinol | Allopurinol | 61 | 19 |
| Eliquis | Apixaban | 61 | 18 |
| Pravastatin Sodium | Pravastatin Sodium | 58 | 17 |
| Breztri Aerosphere | Budesonide/Glycopyr/Formoterol | 57 | 16 |
| Prolia | Denosumab | 57 | 38 |
| Finasteride | Finasteride | 56 | 23 |
| Clopidogrel | Clopidogrel Bisulfate | 52 | 22 |
| Sertraline Hcl | Sertraline Hcl | 51 | 16 |
| Labetalol Hcl | Labetalol Hcl | 48 | 13 |
| Hydralazine Hcl | Hydralazine Hcl | 47 | 16 |
| Nifedipine Er | Nifedipine | 45 | 15 |
| Amoxicillin-Clavulanate Potass | Amoxicillin/Potassium Clav | 44 | 33 |
| Methylprednisolone | Methylprednisolone | 42 | 35 |
| Potassium Chloride | Potassium Chloride | 42 | 14 |
| Clobetasol Propionate | Clobetasol Propionate | 40 | 24 |
| Clonidine Hcl | Clonidine Hcl | 40 | 13 |
| Trelegy Ellipta | Fluticasone/Umeclidin/Vilanter | 40 | 16 |
| Glipizide Er | Glipizide | 39 | 12 |
| Levocetirizine Dihydrochloride | Levocetirizine Dihydrochloride | 39 | 18 |
| Ciprofloxacin Hcl | Ciprofloxacin Hcl | 37 | 27 |
| Ibuprofen | Ibuprofen | 35 | 20 |
| Bupropion Xl | Bupropion Hcl | 34 | suppressed |
| Lantus Solostar | Insulin Glargine,hum.Rec.Anlog | 34 | 16 |
| Levetiracetam | Levetiracetam | 34 | suppressed |
| Montelukast Sodium | Montelukast Sodium | 34 | 15 |
| Ezetimibe | Ezetimibe | 33 | suppressed |
| Mupirocin | Mupirocin | 32 | 17 |
| Dextroamphetamine-Amphetamine | Dextroamphetamine/Amphetamine | 31 | suppressed |
| Clonazepam | Clonazepam | 30 | suppressed |
| Triamcinolone Acetonide | Triamcinolone Acetonide | 30 | 25 |
| Dextroamphetamine-Amphet Er | Dextroamphetamine/Amphetamine | 29 | suppressed |
| Esomeprazole Magnesium | Esomeprazole Magnesium | 29 | 11 |
| Meloxicam | Meloxicam | 29 | 16 |
| Memantine Hcl | Memantine Hcl | 29 | 11 |
| Quetiapine Fumarate | Quetiapine Fumarate | 29 | suppressed |
| Humalog Kwikpen U-100 | Insulin Lispro | 28 | suppressed |
| Ondansetron Odt | Ondansetron | 28 | 18 |
| Ropinirole Hcl | Ropinirole Hcl | 28 | suppressed |
| Spironolactone | Spironolactone | 27 | suppressed |
| Linzess | Linaclotide | 26 | suppressed |
| Acarbose | Acarbose | 25 | suppressed |
| Fenofibrate | Fenofibrate Nanocrystallized | 25 | suppressed |
| Telmisartan | Telmisartan | 25 | suppressed |
| Venlafaxine Hcl Er | Venlafaxine Hcl | 25 | suppressed |
| Escitalopram Oxalate | Escitalopram Oxalate | 24 | 11 |
| Hydroxyzine Hcl | Hydroxyzine Hcl | 24 | 16 |
| Nebivolol Hcl | Nebivolol Hcl | 24 | suppressed |
| Pregabalin | Pregabalin | 24 | suppressed |
| Teriparatide | Teriparatide | 24 | suppressed |
| Hydrocortisone | Hydrocortisone | 23 | 13 |
| Ketoconazole | Ketoconazole | 23 | 16 |
| Torsemide | Torsemide | 23 | suppressed |
| Xarelto | Rivaroxaban | 23 | suppressed |
| Amitriptyline Hcl | Amitriptyline Hcl | 22 | suppressed |
| Fluticasone-Salmeterol | Fluticasone Propion/Salmeterol | 22 | suppressed |
| Nystatin | Nystatin | 22 | 14 |
| Citalopram Hbr | Citalopram Hydrobromide | 21 | suppressed |
| Donepezil Hcl | Donepezil Hcl | 21 | suppressed |
| Amoxicillin | Amoxicillin | 20 | 16 |
| Divalproex Sodium Er | Divalproex Sodium | 20 | suppressed |
| Mirtazapine | Mirtazapine | 20 | suppressed |
| Nano 2nd Gen Pen Needle | Pen Needle, Diabetic | 20 | suppressed |
| Lovastatin | Lovastatin | 19 | suppressed |
| Nitrofurantoin Mono-Macro | Nitrofurantoin Monohyd/M-Cryst | 19 | 17 |
| Phenytoin Sodium Extended | Phenytoin Sodium Extended | 19 | suppressed |
| Risperidone | Risperidone | 19 | suppressed |
| Topiramate | Topiramate | 19 | suppressed |
| Amlodipine Besylate-Benazepril | Amlodipine Besylate/Benazepril | 18 | suppressed |
| Arexvy | Rsvpref3 Antigen/As01e/Pf | 18 | 18 |
| Colchicine | Colchicine | 18 | suppressed |
| Duloxetine Hcl | Duloxetine Hcl | 18 | suppressed |
| Farxiga | Dapagliflozin Propanediol | 18 | suppressed |
| Lactulose | Lactulose | 18 | suppressed |
| Levemir Flexpen | Insulin Detemir | 18 | suppressed |
| Metoclopramide Hcl | Metoclopramide Hcl | 18 | suppressed |
| Novolog Flexpen | Insulin Aspart | 18 | 11 |
| Rybelsus | Semaglutide | 18 | suppressed |
| Fluconazole | Fluconazole | 17 | 15 |
| Oxycodone-Acetaminophen | Oxycodone Hcl/Acetaminophen | 17 | suppressed |
| Sucralfate | Sucralfate | 17 | suppressed |
| Oxybutynin Chloride | Oxybutynin Chloride | 16 | suppressed |
| Temazepam | Temazepam | 16 | suppressed |
| Tizanidine Hcl | Tizanidine Hcl | 16 | suppressed |
| Acetaminophen-Codeine | Acetaminophen With Codeine | 15 | suppressed |
| Betamethasone Dipropionate | Betamethasone Dipropionate | 15 | suppressed |
| Diazepam | Diazepam | 15 | suppressed |
| Olmesartan Medoxomil | Olmesartan Medoxomil | 15 | suppressed |
| Primidone | Primidone | 15 | suppressed |
| Valsartan-Hydrochlorothiazide | Valsartan/Hydrochlorothiazide | 15 | suppressed |
| Celecoxib | Celecoxib | 14 | suppressed |
| Dropsafe Prep Pads | Alcohol Antiseptic Pads | 14 | suppressed |
| Myrbetriq | Mirabegron | 14 | suppressed |
| Tradjenta | Linagliptin | 14 | suppressed |
| Valacyclovir | Valacyclovir Hcl | 14 | suppressed |
| Acyclovir | Acyclovir | 13 | suppressed |
| Carbidopa-Levodopa | Carbidopa/Levodopa | 13 | suppressed |
| Forteo | Teriparatide | 13 | suppressed |
| Hydroxychloroquine Sulfate | Hydroxychloroquine Sulfate | 13 | suppressed |
| Lorazepam | Lorazepam | 13 | suppressed |
| Shingrix | Varicella-Zoster Ge/As01b/Pf | 13 | 13 |
| Alfuzosin Hcl Er | Alfuzosin Hcl | 12 | suppressed |
| Ammonium Lactate | Ammonium Lactate | 12 | suppressed |
| Cefdinir | Cefdinir | 12 | 11 |
| Janumet Xr | Sitagliptin Phos/Metformin Hcl | 12 | suppressed |
| Lacosamide | Lacosamide | 12 | suppressed |
| Paxlovid | Nirmatrelvir/Ritonavir | 12 | suppressed |
| Sumatriptan Succinate | Sumatriptan Succinate | 12 | suppressed |
| Avonex (4 Pack) | Interferon Beta-1a | 11 | suppressed |
| Benazepril Hcl | Benazepril Hcl | 11 | suppressed |
| Breo Ellipta | Fluticasone/Vilanterol | 11 | suppressed |
| Cephalexin | Cephalexin | 11 | suppressed |
| Insulin Lispro Kwikpen U-100 | Insulin Lispro | 11 | suppressed |
| Meclizine Hcl | Meclizine Hcl | 11 | suppressed |
| Prednisone | Prednisone | 11 | suppressed |
| Tasimelteon | Tasimelteon | 11 | suppressed |
| Valsartan | Valsartan | 11 | suppressed |
Timeline
Payment and prescribing data by year
Open Payments and Medicare Part D may refer to different years. They are shown separately rather than aligned as if they describe the same period.
| Year | General Payments | Main payer | Explicit products | Company overlaps | Part D coverage |
|---|---|---|---|---|---|
| 2025 | $533.64 · 26 records | Bayer Healthcare Pharmaceuticals Inc. | ABRYSVO, ACCRUFER, AIRSUPRA, CAPLYTA, COMIRNATY, Cologuard Collection Kit, Fluad, Flucelvax, GEMTESA, GVOKE HYPOPEN, Kerendia, MOUNJARO, NUZYRA, OTEZLA, Ozempic, PREVNAR 20, REPATHA, Rybelsus, VRAYLAR | 8 | — |
| 2024 | — | — | — | — | Complete |
Questions to ask
Questions you could discuss with your doctor
- What role, if any, does Ozempic play in your treatment recommendations for me?
- How do you evaluate evidence when you have a financial relationship with ABBVIE INC.?
- Are there reasonable alternatives I should understand when we discuss treatment options?
- How should I interpret the industry-payment records shown here in the context of my care?
These are general questions generated from reviewed templates. They are not personalized medical advice.
Sources and limitations
How to read this page
- Payment and Medicare prescribing data can cover different years; every comparison shows both years explicitly.
- Part D does not represent a doctor’s entire practice; it excludes many patients and is subject to CMS public-release thresholds.
- Company–drug relationships must have an auditable source, a precise relationship type, and a valid evidence period. Unresolved mappings are not published.
- Generic drug claims are not attributed to a specific manufacturer without manufacturer-level evidence.
- When a source extract is incomplete, missing rows are never treated as proof of no payments or no prescriptions.
Loaded source releases
| Dataset | Year | Publication | Source |
|---|---|---|---|
| CMS Open Payments — General Payments | 2025 | 2026-06-30 | Original source |
| Medicare Part D Prescribers by Provider and Drug | 2024 | 2026-05-06 | Original source |
| NPPES Data Dissemination V2 | current / reference data | 2026-08-10 | Original source |
Full methodology · Questions & answers · Report a possible error